Company intelligence / Profile preview

Synsorb Biotech

Ownership: Private
Development stage: Other

Overview

Synsorb developed oral carbohydrate-based drugs designed to bind and neutralize bacterial toxins rather than kill bacteria directly. Its lead product, Synsorb Pk, was in Phase III trials for prevention of hemolytic uremic syndrome due to verotoxigenic E. coli infection; another product, Synsorb Cd, was in Phase II trials for recurrent Clostridium difficile-associated diarrhea as of the late 1990s/early 2000s. The company also explored cancer therapeutics using reovirus targeting the Ras pathway after acquiring Oncolytics Biotech Inc.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Synthetic carbohydrateSmall molecule
Industry: Biotech

Drug pipeline

1 asset

Synsorb Pk

Partnerships

Ocean Pharmaceuticals Inc. (antibiotics from marine microorganisms)GeneSense Technologies Inc. (antisense technology targeting cancer)

Beyond the preview

Go deeper on Synsorb Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synsorb Biotech.

Explore the full profile